Loading...

Xencor

DB:XE9
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XE9
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
XE9 Share Price and Events
7 Day Returns
-1.8%
DB:XE9
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
12.6%
DB:XE9
-9.2%
DE Biotechs
-6.7%
DE Market
XE9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Xencor (XE9) -1.8% 2.3% -9.5% 12.6% 114.6% 268.4%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • XE9 outperformed the Biotechs industry which returned -9.2% over the past year.
  • XE9 outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
XE9
Industry
5yr Volatility vs Market
Related Companies

XE9 Value

 Is Xencor undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Xencor to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Xencor.

DB:XE9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:XE9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:XE9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Xencor is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:XE9 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 47.78 Analyst x2 44.24
2020 -93.20 Analyst x4 -79.89
2021 -51.63 Analyst x3 -40.97
2022 -50.38 Analyst x2 -37.02
2023 94.07 Analyst x2 63.99
2024 145.43 Est @ 54.6% 91.60
2025 201.12 Est @ 38.29% 117.28
2026 255.17 Est @ 26.87% 137.77
2027 303.34 Est @ 18.88% 151.63
2028 343.63 Est @ 13.28% 159.04
Present value of next 10 years cash flows $607.68
DB:XE9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $343.63 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$4,426.40
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,426.40 ÷ (1 + 8.01%)10
$2,048.58
DB:XE9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $607.68 + $2,048.58
$2,656.25
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,656.25 / 56.29
$47.19
DB:XE9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:XE9 represents 0.86432x of NasdaqGM:XNCR
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86432x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 47.19 x 0.86432
€40.78
Value per share (EUR) From above. €40.78
Current discount Discount to share price of €27.11
= -1 x (€27.11 - €40.78) / €40.78
33.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Xencor is available for.
Intrinsic value
34%
Share price is €27.11 vs Future cash flow value of €40.78
Current Discount Checks
For Xencor to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Xencor's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Xencor's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Xencor's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Xencor's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:XE9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.31
NasdaqGM:XNCR Share Price ** NasdaqGM (2019-04-18) in USD $31.36
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Xencor.

DB:XE9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:XNCR Share Price ÷ EPS (both in USD)

= 31.36 ÷ -1.31

-24.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xencor is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Xencor is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Xencor's expected growth come at a high price?
Raw Data
DB:XE9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -24.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
27%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Xencor, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Xencor's assets?
Raw Data
DB:XE9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $9.27
NasdaqGM:XNCR Share Price * NasdaqGM (2019-04-18) in USD $31.36
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:XE9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:XNCR Share Price ÷ Book Value per Share (both in USD)

= 31.36 ÷ 9.27

3.38x

* Primary Listing of Xencor.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xencor is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Xencor's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Xencor has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

XE9 Future Performance

 How is Xencor expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Xencor expected to grow at an attractive rate?
  • Xencor's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Xencor's earnings growth is expected to exceed the Germany market average.
  • Xencor's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:XE9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:XE9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 27%
DB:XE9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 40.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:XE9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:XE9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 448 36 70 4
2022-12-31 186 -50 -36 4
2021-12-31 112 -50 -93 8
2020-12-31 74 -50 -75 9
2019-12-31 65 55 -63 6
DB:XE9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 41 -80 -70
2018-09-30 49 -70 -55
2018-06-30 20 -63 -81
2018-03-31 32 -47 -63
2017-12-31 46 -34 -38
2017-09-30 22 -43 -55
2017-06-30 30 95 -40
2017-03-31 84 98 15
2016-12-31 109 95 45
2016-09-30 103 107 40
2016-06-30 99 12 38
2016-03-31 34 14 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Xencor's earnings are expected to grow significantly at over 20% yearly.
  • Xencor's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:XE9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Xencor Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XE9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.20 4.77 -1.90 3.00
2022-12-31 -0.66 -0.02 -1.83 3.00
2021-12-31 -1.62 -1.10 -2.08 5.00
2020-12-31 -1.31 -0.10 -2.80 8.00
2019-12-31 -0.95 -0.66 -1.45 4.00
DB:XE9 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.31
2018-09-30 -1.07
2018-06-30 -1.64
2018-03-31 -1.34
2017-12-31 -0.82
2017-09-30 -1.20
2017-06-30 -0.91
2017-03-31 0.34
2016-12-31 1.09
2016-09-30 0.99
2016-06-30 0.95
2016-03-31 -0.43

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Xencor will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Xencor's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Xencor has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

XE9 Past Performance

  How has Xencor performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Xencor's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Xencor does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Xencor's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Xencor's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Xencor's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Xencor Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XE9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 40.60 -70.41 22.23
2018-09-30 48.75 -55.28 20.99
2018-06-30 19.71 -81.09 17.72
2018-03-31 32.21 -62.94 16.86
2017-12-31 46.15 -38.49 17.11
2017-09-30 22.44 -54.92 15.83
2017-06-30 30.26 -40.34 14.66
2017-03-31 83.77 14.55 13.61
2016-12-31 109.02 45.13 12.75
2016-09-30 102.83 40.45 12.19
2016-06-30 98.52 38.49 12.42
2016-03-31 33.52 -17.55 11.90
2015-12-31 27.76 -17.59 10.71
2015-09-30 11.67 -26.70 9.97
2015-06-30 9.02 -22.94 8.92
2015-03-31 8.83 -19.12 7.99
2014-12-31 9.52 -16.42 6.95
2014-09-30 5.60 -18.78 4.45
2014-06-30 7.91 -16.68 2.87
2014-03-31 11.01 85.37 2.06
2013-12-31 10.17 84.51 3.49
2013-09-30 10.85 85.10 2.99
2013-06-30 9.27 86.69 2.85
2013-03-31 8.11 -11.76 2.75
2012-12-31 9.52 -8.59 2.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Xencor has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Xencor has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Xencor improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Xencor's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Xencor has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

XE9 Health

 How is Xencor's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Xencor's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Xencor is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Xencor's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Xencor's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Xencor has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Xencor Company Filings, last reported 3 months ago.

DB:XE9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 521.68 0.00 294.36
2018-09-30 532.27 0.00 271.60
2018-06-30 519.18 0.00 255.41
2018-03-31 537.66 0.00 462.41
2017-12-31 316.46 0.00 224.13
2017-09-30 290.54 0.00 209.95
2017-06-30 301.37 0.00 188.49
2017-03-31 303.75 0.00 154.79
2016-12-31 313.95 0.00 130.14
2016-09-30 202.42 0.00 104.31
2016-06-30 208.60 0.00 91.11
2016-03-31 158.81 0.00 92.36
2015-12-31 162.43 0.00 96.43
2015-09-30 153.32 0.00 127.94
2015-06-30 162.07 0.00 67.89
2015-03-31 169.30 0.00 144.24
2014-12-31 59.29 0.00 54.65
2014-09-30 59.71 0.00 60.92
2014-06-30 65.52 0.01 66.22
2014-03-31 70.07 0.01 72.54
2013-12-31 73.53 0.01 77.98
2013-09-30 4.57 0.01 9.62
2013-06-30 3.99 0.01 11.75
2013-03-31 -19.50 20.94 2.31
2012-12-31 -19.50 20.94 2.31
  • Xencor has no debt.
  • Xencor had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Xencor has sufficient cash runway for more than 3 years based on current free cash flow.
  • Xencor has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 82.3% each year.
X
Financial health checks
We assess Xencor's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Xencor has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

XE9 Dividends

 What is Xencor's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Xencor dividends.
If you bought €2,000 of Xencor shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Xencor's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Xencor's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:XE9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:XE9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Xencor has not reported any payouts.
  • Unable to verify if Xencor's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Xencor's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Xencor has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Xencor's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Xencor afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Xencor has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

XE9 Management

 What is the CEO of Xencor's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bassil Dahiyat
COMPENSATION $4,999,797
AGE 48
TENURE AS CEO 14.2 years
CEO Bio

Dr. Bassil I. Dahiyat, Ph.D. Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat served as Chief Executive Officer of Xencor from August 1997 to 2003. Dr. Dahiyat served as the Chief Scientific Officer of Xencor, Inc. from 2003 to 2005. Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. He is a Director of IgDraSol Inc. He has been a Director of Xencor, Inc. since August 1997. In 2005, Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. Degrees in Biomedical Engineering from Johns Hopkins University. He has been a Director of Kodiak Sciences Inc. since July 2018.

CEO Compensation
  • Bassil's compensation has increased whilst company is loss making.
  • Bassil's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Xencor management team in years:

8.9
Average Tenure
56.5
Average Age
  • The average tenure for the Xencor management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Bassil Dahiyat

TITLE
Co-Founder
COMPENSATION
$5M
AGE
48
TENURE
14.2 yrs

John Kuch

TITLE
Senior VP of Finance
COMPENSATION
$2M
AGE
59
TENURE
8.5 yrs

John Desjarlais

TITLE
Senior VP of Research & Chief Scientific Officer
COMPENSATION
$2M
AGE
54
TENURE
4.8 yrs

Paul Foster

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$2M
AGE
64
TENURE
9.3 yrs

Charles Liles

TITLE
Associate Director and Head of Corporate Communications & Investor Relations
Board of Directors Tenure

Average tenure and age of the Xencor board of directors in years:

3.9
Average Tenure
64
Average Age
  • The tenure for the Xencor board of directors is about average.
Board of Directors

Kurt Gustafson

TITLE
Independent Director
COMPENSATION
$180K
AGE
50
TENURE
4.8 yrs

Bassil Dahiyat

TITLE
Co-Founder
COMPENSATION
$5M
AGE
48
TENURE
21.7 yrs

Alan Montgomery

TITLE
Independent Director
COMPENSATION
$194K
AGE
65
TENURE
4.1 yrs

Richard Ranieri

TITLE
Director
COMPENSATION
$234K
AGE
66
TENURE
1.3 yrs

Richard Lerner

TITLE
Member of Scientific Advisory Board
AGE
80

Jeff Ravetch

TITLE
Member of Scientific Advisory Board
AGE
67
TENURE
9.8 yrs

Yujiro Hata

TITLE
Independent Director
COMPENSATION
$168K
AGE
44
TENURE
3.8 yrs

Kevin Gorman

TITLE
Director
COMPENSATION
$392K
AGE
60
TENURE
2 yrs

Ellen Feigal

TITLE
Director
AGE
64
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Xencor insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Mar 19 Buy John Stafford Individual 22. Mar 19 25. Mar 19 5,500 €26.48 €145,061
19. Mar 19 Buy John Stafford Individual 15. Mar 19 18. Mar 19 39,400 €26.38 €1,009,551
18. Sep 18 Sell John Stafford Individual 14. Sep 18 14. Sep 18 -1,000 €41.21 €-41,206
17. Jul 18 Sell John Stafford Individual 13. Jul 18 17. Jul 18 -111,700 €35.91 €-3,957,952
12. Jul 18 Sell John Stafford Individual 10. Jul 18 12. Jul 18 -138,300 €34.14 €-4,697,713
20. Jun 18 Sell John Stafford Individual 18. Jun 18 20. Jun 18 -250,000 €34.59 €-8,613,885
15. Jun 18 Sell John Kuch Individual 13. Jun 18 13. Jun 18 -25,000 €35.36 €-883,970
X
Management checks
We assess Xencor's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Xencor has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

XE9 News

Simply Wall St News

XE9 Company Info

Description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

Details
Name: Xencor, Inc.
XE9
Exchange: DB
Founded: 1997
$1,555,407,571
56,292,169
Website: http://www.xencor.com
Address: Xencor, Inc.
111 West Lemon Avenue,
2nd Floor,
Monrovia,
California, 91016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM XNCR Common Stock Nasdaq Global Market US USD 03. Dec 2013
DB XE9 Common Stock Deutsche Boerse AG DE EUR 03. Dec 2013
Number of employees
Current staff
Staff numbers
156
Xencor employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:02
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.